ONCY
Quality Rating
This report evaluates Oncocyte Corporation (ONCY), a biotechnology firm specializing in cancer diagnostics, for Shariah compliance. Financial ratios indicate strong performance in debt and liquidity metrics, but insufficient income data leads to some uncertainties. Business activities are permissible, with no non-compliant revenue sources identified. Index inclusion research shows no presence in major Shariah indices, resulting in non-compliant status despite favorable ratios. Overall, the stock requires monitoring for data completeness and potential future index eligibility.
Purification Required
Minimal purification needed for dividend income
Index Inclusion
Not included in any of the four major Shariah-compliant indices
Key Compliance Considerations
- Insufficient data for interest income and non-permissible income ratios, leading to review status in some standards
- Unknown industry classification complicates benchmarking and peer comparisons
- No inclusion in major Shariah indices despite compliant financial ratios
Debt Ratio
1.3%
Liquidity Ratio
20.3%
Interest Income Ratio
0.0%
Purification
0.00%